Clinical trials: Depression NOS
Restless Legs Syndrome, Moderate to Severe Idiopathic Restless Legs Syndrome (RLS)
The Effects Of Ropinirole On Mood Or Mild Depression In Patients With Moderate To Severe Restless Legs Syndrome
Ropinirole has shown to improve mood in depressed patients as well as to improve the symptoms of Restless Legs Syndrome. Up to 40% of RLS patients suffer from mild depression, therefore it would be important for decisions no…
- Trial name
- NCT00357097
- Testing
- Ropinirole
- Where
- 50 sites in Germany
- Volunteers
- 240 people
- Sponsor
- GlaxoSmithKline
Depression, Anxiety
Understanding the Efficacy of Mobile Apps as Intervention for Depression in Adults When Deployed as Part of Primary Care.
The clinical study is meant to optimize the mobile intervention, to develop a robust implementation plan for the mobile intervention within primary care, and to conduct an effectiveness trial, randomizing 128 participants in…
- Conditions
- Depression, Anxiety, Primary Health Care
- Trial name
- NCT03500536
- Testing
- IntelliCare
- Where
- United States
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- Actualize Therapy
Major Depressive Disorder, Depression
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder
The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like medicine tablet or capsule, but contains no active medicine) is safe and effective when taken together with another antidepressant.
- Trial name
- NCT01153347
- Testing
- TC-5214
- Where
- 99 sites in United States, India and 1 more
- Volunteers
- 2,409 people
- Sponsor
- AstraZeneca
Bipolar I Depression
A Study of Lurasidone Compared With Placebo for the Treatment of Bipolar I Depression
The study evaluates the efficacy and safety of lurasidone compared with placebo in treating Bipolar I Depression.
- Trial name
- NCT04383691
- Testing
- Lurasidone HCl
- Where
- 26 sites in China
- Volunteers
- 124 people
- Sponsor
- Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Treatment Resistant Depression
Linear Asymmetric rTMS in Adolescent Treatment-Resistant Depression: Treatment Durations From Ten Days to One Day
This is a pilot interventional study to investigate the acceptability, tolerability, and side effect profile for varying numbers of treatment sessions/day of a new rTMS treatment in adolescents with treatment-resistant depression…
- Trial name
- NCT03986658
- Testing
- Linear Asymmetric rTMS System
- Where
- Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- NeuroQore Inc.
Major Depressive Disorder (MDD)
Efficacy Study of RX-10100 to Treat Major Depressive Disorder (MDD)
The primary objective of this Phase IIa trial is to determine the effective dose and treatment period for an upcoming RX-10100 Phase IIb trial in subjects with major depression disorder (MDD).
- Trial name
- NCT00839176
- Testing
- RX-10100
- Where
- 3 sites in United States
- Volunteers
- 118 people
- Sponsor
- Rexahn Pharmaceuticals, Inc.
Treatment-Resistant Depression
PINS Stimulator System for Patients With Treatment Resistant Depression
Evaluate the effects and safety of Deep Brain Stimulation (DBS) to treat on patients with Treatment-Resistant Depression (TRD) and using functional magnetic resonance imaging (fMRI)to evaluate the influence of acupuncture on…
- Trial name
- NCT02253355
- Testing
- Deep Brain Stimulation
- Volunteers
- 20 people
- Sponsor
- Beijing Pins Medical Co., Ltd
Depressive Disorder, Treatment-Resistant
A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression
The purpose of this study is to evaluate the efficacy of each individual dose of esketamine nasal spray, 56 milligram (mg) and 84 mg, compared with placebo nasal spray in improving depressive symptoms in participants with…
- Trial name
- NCT04599855
- Testing
- Esketamine 56 mg, Esketamine 84 mg
- Where
- 54 sites in United States
- Volunteers
- 477 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorders
Long Term Safety and Tolerability of SR58611 in Patients With Major Depressive Disorder
Primary objective: To evaluate the long-term safety and tolerability of SR58611A (amibegron) patients with major depressive disorder (MDD).
- Trial name
- NCT00855530
- Testing
- amibegron (SR58611A)
- Where
- 11 sites in Argentina, Chile and 9 more
- Volunteers
- 527 people
- Sponsor
- Sanofi
Alzheimer's Disease, Dementia
Safety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease
For many, Alzheimer's disease is the number one medical issue facing our aging society. It is a late onset neurodegenerative disease, frequently under diagnosed, that impairs memory and cognitive performance.
- Conditions
- Alzheimer's Disease, Dementia, Memory Loss, Cognitive Impairment
- Trial name
- NCT01354691
- Testing
- ladostigil hemitartrate
- Where
- 19 sites in Austria, Croatia and 3 more
- Volunteers
- 200 people
- Sponsor
- Avraham Pharmaceuticals Ltd
Postpartum Depressive Disorder
A Phase 2 Study to Evaluate Efficacy and Safety of KH607 Tablets in Woman With Postpartum Depression
This is a study evaluating the efficacy, and safety of KH607 in 72 participants diagnosed with Postpartum Depressive Disorder.
- Trial name
- NCT07096791
- Testing
- KH607 tablet
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Chengdu Kanghong Pharmaceutical Group Co., Ltd.
Treatment-Resistant Depression
Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)
The main purpose of this study was to evaluate safety and efficacy of a single injection of MIJ821 in addition to standard of care (SoC) pharmacological anti-depressant treatment in participants with treatment-resistant…
- Trial name
- NCT05454410
- Testing
- MIJ821 Subcutaneous Injection 1 mg, MIJ821 Subcutaneous Injection 4 mg, MIJ821 Subcutaneous Injection 10 mg
- Where
- 16 sites in United States, Japan and 2 more
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Major Depressive Disorder
Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Depression
The purpose of the study is to determine the efficacy, safety and pharmacokinetics of inhaled Esketamine in participants with treatment-resistant depression (TRD) in the course of Major Depressive Disorder (MDD).
- Trial name
- NCT03965858
- Testing
- Esketamine DPI - low dose, Esketamine DPI - medium dose, Esketamine DPI - high dose
- Where
- 12 sites in Poland
- Volunteers
- 88 people
- Sponsor
- Celon Pharma SA
Depression, Depressive Disorder
Near-infrared Transcranial Laser Therapy in Subjects With Major Depressive Disorder
Major depressive disorder (MDD) is a leading cause of disability worldwide, and many patients do not achieve adequate benefit from current treatments.
- Conditions
- Depression, Depressive Disorder, Depressive Disorder, Major
- Trial name
- ELATED-4 (NCT06934135)
- Testing
- Bilateral Near-Infrared Transcranial Photobiomodulation (tPBM)
- Where
- 2 sites in Peru
- Volunteers
- 50 people
- Sponsor
- NeuroThera DE
Depressive Disorder
Study In Patients With Depression Not Responding to Selective Serotonin Re-uptake Inhibitors
This study is designed to evaluate the efficacy and safety in depressive patients who did not respond sufficiently to selective serotonin re-uptake inhibitors (SSRI).
- Trial name
- NCT00296517
- Testing
- 323U66 (Bupropion Hydrochloride Sustained Release)
- Where
- 62 sites in Japan
- Volunteers
- 325 people
- Sponsor
- GlaxoSmithKline
Stable Angina Pectoris Associated With Depression
The Efficacy and Safety of Ginkgo Biloba Dropping Pills in the Treatment of Coronary Heart Disease With Stable Angina Pectoris and Depression
To evaluate the clinical efficacy of Ginkgo biloba dropping pills on improving the frequency of angina pectoris and the life quality of patients with stable angina pectoris and depression symptoms on the basis of the best western…
- Trial name
- NCT04529148
- Testing
- Ginkgo biloba dropping pills，best western medicine treatment, Mimetic drug of ginkgo biloba dropping pills，best western medicine treatment
- Where
- 4 sites in China
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Wanbangde Pharmaceutical Group Co., LTD
Major Depressive Disorder
A Longitudinal Observational Cohort Study of NSI-189, With Out-Patients With Major Depressive Disorder
All subjects completing the randomized treatment period in Protocol NS2014-1 will discontinue study drug and be asked to provide consent to be followed in this 6-month study, at their final safety visit.
- Trial name
- NCT02724735
- Testing
- NSI-189
- Where
- 12 sites in United States
- Volunteers
- 220 people
- Sponsor
- Neuralstem Inc.
Seasonal Affective Disorder
Prevention of Seasonal Affective Disorder
This is a placebo controlled study evaluating the effectiveness of medication in preventing depressive episodes in subjects with a history of Seasonal Affective Disorder (SAD).
- Trial name
- NCT00046241
- Testing
- Extended-release bupropion hydrochloride
- Where
- 51 sites in United States, Canada
- Volunteers
- 300 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
The primary objectives of this study are to: 1) Evaluate the efficacy of CP 601,927 compared to placebo in the augmentation of antidepressant therapy (ADT) in patients with Major Depressive Disorder (MDD) using the Montgomery…
- Trial name
- NCT01098240
- Testing
- CP-601,927
- Where
- 58 sites in United States
- Volunteers
- 297 people
- Sponsor
- Pfizer
Anxiety Disorders, Depression
TAO Outpatient Trial for Anxiety and Depression
Access to effective treatment resources is a ubiquitous problem in behavioral health. There is a need for effective interventions that are more easily accessed at a lower cost.
- Trial name
- NCT03390218
- Testing
- Therapy Assistance Online, Treatment as usual
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- TAO Connect, Inc.